Form 8-K - Current report:
SEC Accession No. 0001493152-24-032926
Filing Date
2024-08-19
Accepted
2024-08-19 06:06:03
Documents
17
Period of Report
2024-08-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45149
2 ex5-1.htm EX-5.1 12314
3 ex5-1_001.jpg GRAPHIC 3862
4 ex5-1_002.jpg GRAPHIC 4271
  Complete submission text file 0001493152-24-032926.txt   290227

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cing-20240815.xsd EX-101.SCH 3781
6 XBRL DEFINITION FILE cing-20240815_def.xml EX-101.DEF 26635
7 XBRL LABEL FILE cing-20240815_lab.xml EX-101.LAB 36718
8 XBRL PRESENTATION FILE cing-20240815_pre.xml EX-101.PRE 25259
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5714
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 241218183
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)